Romosozumab - Amgen/UCB

Drug Profile

Romosozumab - Amgen/UCB

Alternative Names: AMG-785; Anti-sclerostin; Anti-sclerostin monoclonal antibody; CDP-7851; EVENITY; Sclerostin Ab

Latest Information Update: 07 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator UCB
  • Developer Amgen; UCB
  • Class Monoclonal antibodies; Osteoporosis therapies
  • Mechanism of Action SOST protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Male osteoporosis; Postmenopausal osteoporosis
  • Discontinued Fracture

Most Recent Events

  • 14 May 2018 Amgen completes a phase III trial for Postmenopausal osteoporosis in South Korea (SC) (NCT02791516)
  • 07 Jan 2018 Preregistration for Male osteoporosis in European Union (SC) before January 2018
  • 07 Jan 2018 Preregistration for Postmenopausal osteoporosis in European Union (SC) before January 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top